Neuberger Berman Group LLC Raises Stock Holdings in Insmed, Inc. $INSM

Neuberger Berman Group LLC grew its position in Insmed, Inc. (NASDAQ:INSM) by 1,277.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 150,106 shares of the biopharmaceutical company’s stock after acquiring an additional 139,211 shares during the quarter. Neuberger Berman Group LLC owned about 0.07% of Insmed worth $21,617,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Stone House Investment Management LLC acquired a new stake in Insmed during the 3rd quarter worth $29,000. SBI Securities Co. Ltd. raised its position in Insmed by 404.9% during the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 166 shares during the last quarter. MassMutual Private Wealth & Trust FSB raised its position in Insmed by 59.6% in the third quarter. MassMutual Private Wealth & Trust FSB now owns 217 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 81 shares in the last quarter. Whittier Trust Co. of Nevada Inc. boosted its position in shares of Insmed by 169.7% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 240 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 151 shares in the last quarter. Finally, AlphaQuest LLC grew its stake in shares of Insmed by 109.5% during the 3rd quarter. AlphaQuest LLC now owns 287 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 150 shares during the period.

Insider Transactions at Insmed

In other Insmed news, insider Michael Alexander Smith sold 640 shares of Insmed stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $156.27, for a total value of $100,012.80. Following the completion of the transaction, the insider owned 56,397 shares of the company’s stock, valued at $8,813,159.19. The trade was a 1.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, COO Roger Adsett sold 791 shares of the business’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $156.17, for a total transaction of $123,530.47. Following the sale, the chief operating officer owned 106,810 shares of the company’s stock, valued at approximately $16,680,517.70. The trade was a 0.74% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 189,651 shares of company stock valued at $31,784,545. 3.00% of the stock is currently owned by insiders.

Insmed Stock Down 2.4%

Shares of Insmed stock opened at $140.13 on Friday. The business has a 50-day moving average price of $158.58 and a 200 day moving average price of $165.58. Insmed, Inc. has a fifty-two week low of $60.40 and a fifty-two week high of $212.75. The firm has a market cap of $30.21 billion, a P/E ratio of -21.86 and a beta of 1.13. The company has a quick ratio of 3.54, a current ratio of 3.83 and a debt-to-equity ratio of 0.76.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) EPS for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). The firm had revenue of $263.84 million for the quarter, compared to the consensus estimate of $263.97 million. Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The company’s quarterly revenue was up 152.6% on a year-over-year basis. During the same period in the prior year, the business earned ($1.32) EPS. On average, sell-side analysts forecast that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Wolfe Research set a $167.00 price objective on Insmed and gave the company an “outperform” rating in a research note on Thursday, December 18th. Rothschild & Co Redburn set a $263.00 price target on Insmed in a research note on Thursday, December 4th. Bank of America set a $203.00 target price on Insmed in a report on Thursday, December 18th. TD Cowen set a $241.00 price target on shares of Insmed in a report on Thursday, December 18th. Finally, Leerink Partners reiterated an “outperform” rating on shares of Insmed in a research note on Thursday, December 18th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $207.52.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.